Abstract: Provided is a method for producing a chlorophenoxycarboxylate, comprising the following steps of: a phenoxycarboxylate under actions of a catalyst A and a catalyst B performing a selective chlorination of a chlorinating agent at a 2-position and/or a 4-position to obtain the chlorophenoxycarboxylate; the catalyst A is a Lewis acid; and the catalyst B has the following structure: R1?—S—R2?. The present disclosure redesigns the process route, and finely screens the catalyst and the chlorinating agent, thereby effectively improving the chlorination selectivity while avoiding the loss of the active ingredient, and the content of the obtained chlorophenoxycarboxylate can reach more than 98.5%, and the yield can reach more than 99%.

Abstract: A reactor tank is provided having an enzyme inlet, a heating jacket positioned around the exterior center of the tank, a gas outlet for communicating with a vacuum apparatus to create a vacuum within the reactor tank and for communicating with a condensing unit, a first gas inlet for receiving gas from a feed tank and a first liquid outlet for recirculating the liquid from the first liquid outlet back to the feed tank. The reactor tank further includes a sparged unit and a screen positioned within the tank between the sparged unit and the first liquid outlet, where the sparged unit is connected to the first gas inlet for receiving gas from the feed tank.

Abstract: The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

Abstract: A reactor tank is provided having an enzyme inlet, a heating jacket positioned around the exterior center of the tank, a gas outlet communicating with a vacuum apparatus and a condensing unit, a first gas inlet for receiving gas from a feed tank and a first liquid outlet for recirculating the liquid back to the feed tank. The tank further includes a sparged unit connected to the first gas inlet for receiving gas from the feed tank and a screen positioned between the sparged unit and the first liquid outlet. The reactor tank is utilized in a reactor system further including a condensing unit, vacuum pump or venturi valve, a first feed tank, a coalescer having at least one circulation pipe and a first circulation pump.

Abstract: A compound of formula (I) wherein Rf is —CF3, —C2F5, or —CF2CFXCF3; X is —F, or —OC3F7; Y is —H, —Cl, or —Br; R is —OH, —(OCH2CH2)mOH, —(CH2)n(OCH2CH2)mOH, —O—C(O)—R1, —(CH2)nO—C(O)R1, —(OCH2CH2)mOC(O)—R1, —C(O)NHw(CH2CH2OH)2-w, —C?N, —C?CH; n is 1 to 10; m is 1 to 10; R1 is C1 to C10 alkyl; a is 1 to 5; b is 1 to 5; and w is 0, 1 or 2.

Abstract: The present invention provides methods and intermediates for the preparation of (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract: The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.

Abstract: The present application discloses a process for the preparation of a halofenate compound of the formula (III) or a salt thereof: wherein R, X and X? are as defined herein, the process comprising contacting a compound of formula (Ia) with a compound of formula (Ib) and N,N?-dicyclohexylcarbodiimide under conditions sufficient to form the compound of formula (III).

Abstract: A radiation-sensitive composition containing a resist compound having a high sensitivity, a high resolution, a high etching resistance, and a low outgas which forms a resist pattern with good shape and a method of forming a resist pattern and novel compositions for forming a photoresist under coat film which is excellent in optical properties and etching resistance and contains substantially no sublimable substance and an under coat film formed by the composition. Radiation-sensitive composition containing a solvent and a cyclic compound having, e.g., a cyclic compound (A) having a molecular weight of 700 to 5000 which is synthesized by the condensation reaction of a compound having 2 to 59 carbon atoms and 1 to 4 formyl groups with a compound having 6 to 15 carbon atoms and 1 to 3 phenolic hydroxyl groups, and a cyclic compound for use in the radiation-sensitive composition.

Abstract: The present invention relates to esters of carboxylic acid agrochemicals comprising a labile protecting group and having formula (I). Certain of the esters of carboxylic acid agrochemicals do not undergo hydrolysis to a significant degree in the dark, but are cleaved to regenerate the parent carboxylic acid agrochemical when exposed to light. Others of the esters of carboxylic acid agrochemicals undergo hydrolysis under both light and dark conditions. The present invention further relates to methods for the controlled release of a carboxylic acid agrochemicals, and to methods of controlling unwanted plants comprising applying to the unwanted plants an ester of a carboxylic acid agrochemical.

Abstract: The present application discloses a process for the preparation of a halofenate compound of the formula (III) or a salt thereof: wherein R, X and X? are as defined herein, the process comprising contacting a compound of formula (Ia) with a compound of formula (Ib) and N,N?-dicyclohexylcarbodiimide under conditions sufficient to form the compound of formula (III).

Abstract: The present invention discloses a method of purification of prostaglandins including fluorine atoms by using preparative HPLC. Tafluprost and Travoprost are prostaglandins including fluorine. The chemical structure of the impurities in crude Tafluprost and crude Travoprost also contain fluorine, therefore, the removal of the impurities is difficult. Purification by using preparative high performance liquid chromatography (HPLC) can achieve high-quality liquid bulk drugs.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: A polymerizable fluorine-containing compound represented by formula (1), wherein R1 represents a polymerizable double-bond containing group, R2 represents an acid-labile protecting group, R3 represents a fluorine atom or fluorine-containing alkyl group, and W represents a bivalent linking group. This compound can provide a fluorine-containing polymer compound that has a weight-average molecular weight of 1,000-1,000,000 and contains a repeating unit represented by formula (2), wherein R2, R3 and W are defined as above, each of R4, R5 and R6 independently represents a hydrogen atom, fluorine atom or monovalent organic group, at least two of R4, R5 and R6 may be combined to form a ring. This polymer compound can provide a resist composition capable of forming a pattern that is transparent to exposure light and superior in rectangularity.

Abstract: The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate.

Abstract: A diamine compound of formula (I) is proposed as well as polymers, copolymers, polyamic acids, polyamic acid esters, or polyimides based on such compound.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate.

Abstract: The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.

Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6 , n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.

Abstract: The racemic and chiral compounds expressed by common formula 1 and formula 2: wherein the lateral substituents X1, X2, X3, X4, X5, X6, X7 and X8 in the benzene rings represent independently hydrogen and fluorine atoms, bridge group Z represent independently the single bond or COO, CH2CH2, CH2O and OCH2 group, substituent Y represents CH3, or CH2F, CHF2, CF3, C2H5 group, symbols n, m, r and t are independently integers of 1 to 8; symbols p and s signify independently number of 0 to 1 and its orthoconic antiferroelectric long helical pitch mixtures prepared by the methods 1) to the racemic components selected from compounds 1 are added chiral components selected from the compound of formula 1 and/or chiral components selected from the compounds of formula 2 and/or another optically active compounds with high helical twisting power, 2) to chiral compound 1 which helical pitches increases with the temperature increase is added chiral compound 1 which helical pitch decreases with temperature increase.

Abstract: This disclosure relates to reagents and methods useful in the synthesis of aryl fluorides, for example, in the preparation of 18F labeled radiotracers. The reagents and methods provided herein may be used to access a broad range of compounds, including aromatic compounds, heteroaromatic compounds, amino acids, nucleotides, and synthetic compounds.

Abstract: The invention relates to compounds represented by Formula (1): wherein Ra is alkyl or the like; Rb is fluorine or —CF3; A is 1,4-cyclohexylene, 1,4-phenylene or the like; Z is a single bond, alkylene or the like; Y is a single bond, alkylene or the like; and m and n are an integer of approximately 0 to approximately 5.

Abstract: New fluorinated ethers of aromatic acids and diesters are disclosed. These compositions can be applied to, e.g., fibers, yarns, carpets, garments, films, molded parts, paper and cardboard, stone, and tile to impart soil, water and oil resistance. By incorporating the fluorinated ethers of aromatic acids, or diesters thereof, into polymer backbones, more lasting soil, water and oil resistance, as well as improved flame retardance, can be achieved.

Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.

Abstract: A liquid crystal composition comprising at least one compound having a fluorobicyclo[2.2.2]octane skeleton represented by formula (I) below is disclosed. A fluorobicyclo[2.2.2]octane compound represented by formula (II) below is also disclosed. In the formulae, Y represents a hydrogen atom or fluorine atom.

Abstract: The invention relates to compounds of the formula I: and to the pharmaceutically acceptable salts thereof, to processes for the preparation of them and to pharmaceutical compositions comprising them, which are useful especially for the treatment and prevention of dyslipidaemia, atherosclerosis and diabetes.

Abstract: Nitroderivatives of prostaglandin amides having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: A liquid crystal compound represented by the formula CH2?CR1—COO-(L)k-E1-E2-E3-E4-R2 wherein R1: a hydrogen atom or a methyl group; R2: a C1-8 alkyl group; k: 0 or 1; L: —(CH2)pO— or —(CH2)q— (wherein each of p and q which are independent of each other, is an integer of from 2 to 8); E1: a 1,4-phenylene group; E2, E3, E4: each independently a 1,4-phenylene group or a trans-1,4-cyclohexylene group and at least one of E2 and E3 is a trans-1,4-cyclohexylene group, provided that the 1,4-phenylene group and trans-1,4-cyclohexylene group in E1 to E4, may be such that a hydrogen atom bonded to a carbon atom in each group may be substituted by a fluorine atom, a chlorine atom or a methyl group. To provide a novel liquid crystal compound for preparing an optical element which can exhibit a proper Rd value depending upon usable wavelength and application and which is excellent in durability against a blue laser beam.

Abstract: The invention relates to a polymerisable liquid crystal (LC) material, to optically biaxial films prepared thereof, to novel polymerisable compounds used therein and to the use of the material and films in optical devices like compensators and LC displays (LCDs).

Abstract: A pyridazine compound represented by formula (1): has an excellent plant disease controlling effect.

Abstract: This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.

Abstract: The present invention provides a methods and compounds for producing an enantiomerically enriched ?-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where R1 is alkyl or haloalkyl and X is halide.

Abstract: Disclosed is a fluorine-containing compound represented by formula (1), wherein R1 represents a polymerizable double-bond containing group, R2 represents an acid-labile protecting group, R3 represents a fluorine atom or fluorine-containing alkyl group, and W represents a bivalent linking group. This compound can provide a fluorine-containing polymer compound that has a weight-average molecular weight of 1,000-1,000,000 and contains a repeating unit represented by formula (2), wherein R2, R3 and W are defined as above, each of R4, R5 and R6 independently represents a hydrogen atom, fluorine atom or monovalent organic group, at least two of R4, R5 and R6 may be combined to form a ring. This polymer compound can provide a resist composition capable of forming a pattern that is transparent to exposure light and superior in rectangularity.

Abstract: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, to their use for the treatment of dyslipidaemia, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to the processes for the preparation of these compounds.

Abstract: The present invention provides a methods and compounds for producing an enantiomerically enriched ?-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where R1 is alkyl or haloalkyl and X is halide.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: The invention relates to a polymerisable liquid crystal (LC) material, to optically biaxial films prepared thereof, to novel polymerisable compounds used therein and to the use of the material and films in optical devices like compensators and LC displays (LCDs).

Abstract: The present invention provides a novel organic semiconductor material that affords efficient charge transport, under a wider range of conditions, by increasing the temperature stability and expanding the temperature range of the organic semiconductor material. In an organic semiconductor material comprising a liquid crystalline compound having substituents on the periphery of a rigid plate-like central structure, the substituents have a fluorinated phenylene group, and columns in which the molecules of the compound are accumulated in a stack are aligned hexagonally.

Abstract: A one-step process for the preparation of fluoroalkoxystyrene by contacting fluorinated olefin with a solution of hydroxystyrene is disclosed.

Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: The present invention provides a method for producing an enantiomerically enriched ?-(phenoxy)phenylacetic acid compound of the formula (I): from its enantiomeric mixture, where R1 is alkyl or haloalkyl R7 is heteroalkyl and X is halide.

Abstract: The present invention provides a compound represented by formula (1) defined in the specification and a liquid crystal composition comprising the compound. The invention further provides a polymer obtained by polymerization of compound or composition above, and further the present invention provides a film, an optical anisotropic material, A ¼ or ½ wavelength functional plate, an optical compensation element, an optical element and a liquid crystal display element employing the polymer.

Abstract: A process for the preparation of fibrates of formula I in which R1 is a halogen atom, a 2,2-dichloro-cyclopropyl group, a (4-chlorophenyul)-hydroxymethyl group, a-4-chlorobenzoyl group or a 2-(4-chlorobenzamido)-ethyl group, and R2 is hydrogen or a C1-C4 alkyl group.

Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? suptype.

Abstract: The present invention relates to the compounds of the general formula (I) and their salts and stereoisomers for the production of medicaments for the treatment of cardiovascular disorders.

Abstract: A method of synthesizing highly optically enriched &agr;-halo-esters comprises reacting acid halides with a cinchona alkaloid catalyst and a base to form intermediate ketenes. The ketenes are reacted with electrophilic halogenating reagents to produce &agr;-halo-esters with high enantiomeric excess. The base can be an inorganic salt. The thus-formed &agr;-halo-esters have utility in synthesizing other optically-pure materials.

Abstract: Compounds that are useful as components in liquid crystal compositions, particularly in ferroelectric liquid crystal compositions. Compounds of the invention are rod-like molecules with a mesogenic (generally linear) core to which an alkene tail and an alkyl or alkoxy tail with a perfluoroalkyl terminal portion are bonded. Compounds of the invention can contain a variety of one, two or three ring cores, wherein the rings maybe aromatic or alicyclic. Alkenes of the invention are useful as components to improve LC properties of mixtures, for example, to lower melting point of lower freezing point, of LC compositions.